| FTICR-MS discovery | MRM validation | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
 | Genomics Collaborative | Seracare 1 | Osaka | Chiba | Seracare 2 | |||||
 | CRC | Control | CRC | Control | CRC | Control | CRC | Control | CRC | Control |
Total | 40 | 50 | 26 | 25 | 46 | 35 | 40 | 40 | 70 | 70 |
Male N | 19 | 24 | 17 | 16 | 27 | - | 19 | 24 | 44 | 41 |
Male age | 59 (30-78) | 56 (30-78) | 62 (46-80) | 51 (35-70) | 63 (28-90) | - | 68 (45-91) | 48 (36-69) | 67 (39-87) | 63 (32-82) |
Male BMI | 20.9 ± 3.8 | 25.0 ± 0.9 | 24.3 ± 5.7 | 25.6 ± 4.6 | NA | - | NA | NA | 28.0 ± 4.8 | 26. ± 4.2 |
Female N | 21 | 26 | 9 | 9 | 19 | - | 21 | 16 | 26 | 29 |
Female age | 54 (40-82) | 55 (40-79) | 78 (59-86) | 55 (26-95) | 65 (31-77) | - | 70 (51-84) | 49 (39-59) | 73 (35-90) | 56 (26-86) |
Female BMI | 19.9 ± 4.6 | 24.8 ± 2.2 | 23 ± 3.2 | 29 ± 8.0 | NA | - | NA | NA | 25.5 ± 4.4 | 24.0 ± 4.5 |
Stage 0/I | 8 | - | 5 | - | 10 | - | 9 | - | 13 | - |
Stage II | 16 | - | 8 | - | 14 | - | 18 | - | 21 | - |
Stage III | 15 | - | 8 | - | 12 | - | 11 | - | 25 | - |
Stage IV | 1 | - | 2 | - | 8 | - | 2 | - | 7 | - |
Unknown | 0 | - | 3 | - | 2 | - | 0 | - | 4 | - |